Effective depletion of regulatory T cells allows the recruitment of mesothelin-specific CD8 T cells to the antitumor immune response against a mesothelin-expressing mouse pancreatic adenocarcinoma.
about
Inflammatory networks and immune surveillance of pancreatic carcinomaA Listeria vaccine and depletion of T-regulatory cells activate immunity against early stage pancreatic intraepithelial neoplasms and prolong survival of mice.A dendritic cell vaccine pulsed with autologous hypochlorous acid-oxidized ovarian cancer lysate primes effective broad antitumor immunity: from bench to bedside.Immunotherapy converts nonimmunogenic pancreatic tumors into immunogenic foci of immune regulationThe human cancer antigen mesothelin is more efficiently presented to the mouse immune system when targeted to the DEC-205/CD205 receptor on dendritic cells.Immunomodulatory effects of cyclophosphamide and implementations for vaccine design.A safety and feasibility study of an allogeneic colon cancer cell vaccine administered with a granulocyte-macrophage colony stimulating factor-producing bystander cell line in patients with metastatic colorectal cancer.A novel survival-based tissue microarray of pancreatic cancer validates MUC1 and mesothelin as biomarkers.Challenges and future directions in therapeutics for pancreatic ductal adenocarcinoma.PD-1/PD-L1 blockade together with vaccine therapy facilitates effector T-cell infiltration into pancreatic tumors.Cytotoxic activity of immunotoxin SS1P is modulated by TACE-dependent mesothelin shedding.A preclinical murine model of hepatic metastases.Galectin-3 Shapes Antitumor Immune Responses by Suppressing CD8+ T Cells via LAG-3 and Inhibiting Expansion of Plasmacytoid Dendritic Cells.Incorporation of porcine adenovirus 4 fiber protein enhances infectivity of adenovirus vector on dendritic cells: implications for immune-mediated cancer therapy.STING agonist formulated cancer vaccines can cure established tumors resistant to PD-1 blockade.The tipping point for combination therapy: cancer vaccines with radiation, chemotherapy, or targeted small molecule inhibitorsAn effective cytokine adjuvant vaccine induces autologous T-cell response against colon cancer in an animal model.Low-dose cyclophosphamide administered as daily or single dose enhances the antitumor effects of a therapeutic HPV vaccine.Functional p38 MAPK identified by biomarker profiling of pancreatic cancer restrains growth through JNK inhibition and correlates with improved survival.A Phase I vaccine trial using dendritic cells pulsed with autologous oxidized lysate for recurrent ovarian cancer.Expansion of tumor-infiltrating lymphocytes (TIL) from human pancreatic tumors.Therapeutic PD-1 pathway blockade augments with other modalities of immunotherapy T-cell function to prevent immune decline in ovarian cancerDefinitive activation of endogenous antitumor immunity by repetitive cycles of cyclophosphamide with interspersed Toll-like receptor agonists.Immune modulation by chemotherapy or immunotherapy to enhance cancer vaccines.TGF-β blockade depletes T regulatory cells from metastatic pancreatic tumors in a vaccine dependent manner.Dendritic cells fused with different pancreatic carcinoma cells induce different T-cell responsesCAR T-cell therapy for pancreatic cancer.Targeting the right regulatory T-cell population for tumor immunotherapy.Tumor immunology: multidisciplinary science driving basic and clinical advances.Crosstalk between Regulatory T Cells and Tumor-Associated Dendritic Cells Negates Anti-tumor Immunity in Pancreatic Cancer.Targeting cytokine therapy to the pancreatic tumor microenvironment using PD-L1 specific VHHs.Strategies for Increasing Pancreatic Tumor Immunogenicity.Development of improved therapeutic mesothelin-based vaccines for pancreatic cancer.KRAS RENAISSANCE(S) in Tumor Infiltrating B Cells in Pancreatic CancerExploring optimal sequencing of radiation and immunotherapy combinations
P2860
Q27013983-334B077E-1619-4C54-B4ED-9D9DAC1DCB78Q33671350-394824F8-79FC-4C91-B00B-3CF913964150Q33724878-D18479CB-AA89-4331-B93D-E336378C6E19Q33848077-8428A46D-89F9-42A6-9BE9-FCAAD9AFC73FQ34103645-2F166A90-A9DB-4A82-9704-9D49F1CD68F8Q34187201-0BCE37BA-62B9-4D64-82F5-64F0E9EC593AQ34315863-71F8AB57-88A2-4287-81FB-853BF401D83EQ34335982-5AA0E6B3-FE30-4482-BFF2-EF5225150D4FQ34431614-1BF3789D-D1E7-409D-9651-7464EA91BF89Q34644359-492CFBE4-C209-4672-95AA-4382A6D792F3Q35190612-25D0F20F-BA42-4760-A938-EB2A16284D34Q35229297-921CCBB4-4583-4729-B663-01CF1A61C3D0Q35329234-2190DC3D-C372-4C19-A3B9-600C9016C917Q35620238-A59A24CB-24A9-470E-879B-D35CB6583101Q35858368-566754F1-1B7B-4181-9C72-4FF8C0025A2BQ35975387-9C4AE521-1A4D-42A0-BD85-1F343143414BQ36145145-46DBF8CA-61E1-4793-AD62-EA1265006379Q36527473-CBC63B4C-A304-4CA1-B453-BA661F6826C7Q36899872-4950BCEB-B49B-4A18-9949-376222E60469Q36958112-7267FA13-A27B-41A8-98DC-CC0F37DFE6C6Q37346107-15674E55-4813-4A49-B007-2173D3D6D6BFQ37365673-6105DE77-2DA9-4A0E-BE38-1BC2F21376AFQ37536440-91EF2F30-D255-49B3-A3B4-CDB7F512A17FQ38161367-224161FC-C4FF-4CDF-8B10-C57342F839E0Q38632049-DAEDBA35-3163-4677-8665-F55E20D75CD5Q39200045-20C8BA16-0929-49FA-B30E-F12012F3D928Q39202440-12BA4915-5402-4CA4-BB71-B5FD5E92AFDDQ41274940-309D9964-8D8C-49C2-8D1F-BBE2A6930693Q41853258-34914AFD-9101-418A-9C8B-A5136146F974Q42660198-C837D81E-4468-49DF-B942-1EC68944A289Q49832296-116743DE-900F-4C7F-B06A-D9F5F036AB2BQ52691832-71A2B9C7-8B5D-4052-9B3E-F22247A2D70BQ55001866-9EB7216B-BE7A-4585-835B-B3633069604FQ57072901-8CFA70F6-71BF-462F-810D-FCE200D7F131Q58119202-48FA3F56-7E53-42E1-B9CA-B5DE7811D09E
P2860
Effective depletion of regulatory T cells allows the recruitment of mesothelin-specific CD8 T cells to the antitumor immune response against a mesothelin-expressing mouse pancreatic adenocarcinoma.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh
2008年學術文章
@zh-hant
name
Effective depletion of regulat ...... use pancreatic adenocarcinoma.
@en
Effective depletion of regulat ...... use pancreatic adenocarcinoma.
@nl
type
label
Effective depletion of regulat ...... use pancreatic adenocarcinoma.
@en
Effective depletion of regulat ...... use pancreatic adenocarcinoma.
@nl
prefLabel
Effective depletion of regulat ...... use pancreatic adenocarcinoma.
@en
Effective depletion of regulat ...... use pancreatic adenocarcinoma.
@nl
P2093
P2860
P1476
Effective depletion of regulat ...... use pancreatic adenocarcinoma.
@en
P2093
Ihid C Leao
Priya Ganesan
Todd D Armstrong
P2860
P304
P356
10.1111/J.1752-8062.2008.00070.X
P407
P577
2008-12-01T00:00:00Z